Treatment of Severe Autoimmune Hepatitis Refractory to Medical Therapy

Initial Management Approach

The American Association for the Study of Liver Diseases recommends that patients with severe autoimmune hepatitis who fail to respond to corticosteroid therapy should be considered for early liver transplantation, particularly those showing no improvement or worsening in liver biochemistry, synthetic function, or hepatic encephalopathy after 2 weeks of treatment 1, 2
All decompensated patients with severe autoimmune hepatitis should receive a trial of high-dose corticosteroids (1 mg/kg/day prednisone alone or in combination with azathioprine) before proceeding to transplantation, even those with advanced liver disease, ascites, or low-grade hepatic encephalopathy 3, 1, 2
Corticosteroids should be initiated early, ideally before the onset of hepatic encephalopathy, as treated patients have better survival rates than untreated patients 1, 2

The likelihood of treatment success can be determined within 2 weeks of initiating corticosteroids, with favorable indicators including resolution of at least one laboratory abnormality, improvement in hyperbilirubinemia, or failure of any test to worsen during treatment 3, 4, 5
Poor prognosis indicators include presence of multiacinar necrosis on biopsy and hyperbilirubinemia that does not improve after 2 weeks, which predicts the need for urgent transplantation 3, 4, 5

Liver transplantation should be considered in patients with no improvement or worsening in liver biochemistry and synthetic function parameters despite corticosteroid therapy 1
The American Association for the Study of Liver Diseases recommends liver transplantation for patients with development or worsening of hepatic encephalopathy on treatment 1
Patients with ascites, which is the most common indication for decompensation, should also be considered for liver transplantation 3, 4

5-year survival rates exceed 75-92% in adults, with 10-year actuarial survival of 75% 4, 6, 7, 8, 9
Recurrent autoimmune hepatitis occurs in approximately 32% of adults post-transplant, but is typically mild and easily managed 4, 6, 7, 8, 9

Treatment failure occurs in 5-15% of children with autoimmune hepatitis, and children who deteriorate despite corticosteroid compliance should be managed similarly to adults and considered for liver transplantation 3, 4, 5
The frequency of recurrent autoimmune hepatitis in the allograft is greater in children than adults, and recurrent disease has been less uniformly responsive to treatment, resulting in graft loss in several pediatric patients 3, 4, 5

The American Association for the Study of Liver Diseases recommends liver transplantation in AIH patients with acute liver failure, decompensated cirrhosis with MELD score ≥15, or hepatocellular carcinoma meeting transplant criteria 10
Decompensated cirrhosis with MELD score ≥15 is a Class I indication for liver transplantation, as recommended by the American Association for the Study of Liver Diseases 10
Retransplantation must be considered for patients with refractory recurrent AIH progressing to allograft loss, according to the American Association for the Study of Liver Diseases 10
HCC meeting standard transplant criteria (typically Milan criteria) in the setting of AIH-related cirrhosis is an indication for transplantation, as per the American Association for the Study of Liver Diseases 10